Figure 5.

CCR7 siRNA inhibits prostate cancer cells growth in vivo. A. PC-3 siCCR7 or control cells were subcutaneously implanted into mice to build prostate cancer xenograft. On day 25 post injection, tumors were removed and photographed. CCR7 siRNA resulted in significantly tumor growth inhibition versus control mice. Data were from three independent experiments and were average ± S.E. values. n=6, **P<0.01, compared to mice injected with control cells. B. VEGFC, CD31, and MMP-2/9 expression in tumor sections from different mice group was detected by western blot with the antibodies.